Taysha Gene Therapies (NASDAQ:TSHA) Upgraded at Truist Financial

Truist Financial upgraded shares of Taysha Gene Therapies (NASDAQ:TSHA) to a strong-buy rating in a research note published on Wednesday,Zacks.com reports.

Other analysts also recently issued research reports about the stock. UBS Group set a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, December 4th. Raymond James Financial restated a “strong-buy” rating and issued a $13.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, January 6th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Wall Street Zen upgraded Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Finally, Wells Fargo & Company boosted their price objective on Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and a consensus price target of $11.09.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $4.07 on Wednesday. The company has a fifty day simple moving average of $4.58 and a 200-day simple moving average of $4.59. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -11.97 and a beta of 1.02. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $6.02.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to the consensus estimate of $1.89 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 56.64%. On average, equities analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Transactions at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $4.71, for a total value of $942,000.00. Following the sale, the insider directly owned 1,006,439 shares in the company, valued at approximately $4,740,327.69. The trade was a 16.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sean P. Nolan sold 136,789 shares of the company’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the transaction, the chief executive officer directly owned 2,949,569 shares in the company, valued at $14,010,452.75. The trade was a 4.43% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors have recently made changes to their positions in the stock. Marex Group plc acquired a new position in shares of Taysha Gene Therapies in the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. acquired a new stake in Taysha Gene Therapies in the 2nd quarter valued at approximately $31,000. ST Germain D J Co. Inc. raised its position in Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock valued at $32,000 after purchasing an additional 4,333 shares during the period. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in Taysha Gene Therapies in the third quarter valued at approximately $40,000. Finally, Tower Research Capital LLC TRC lifted its stake in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after purchasing an additional 10,742 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.